Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Double-blind Trial of Nintedanib in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome Grade 1–2
2018-001747-31Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bronchiolitis Obliterans Syndrome (BOS) and Bronchiolitis Obliterans (BO) comparing Nintedanib arm with Placebo arm (2 arms). Primary endpoint: Change in FEV1 over 6 months. Started Dec 2018; status: active.
02
Drugs
nintedanib
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)Bronchiolitis Obliterans (BO)
Beyond the preview
Go deeper on 2018-001747-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001747-31.